What is the translation of " IS NOT A SUBSTRATE " in Slovenian?

• ni substrat

Examples of using Is not a substrate in English and their translations into Slovenian

Fampridine is not a substrate for P-glycoprotein.
Fampridin ni substrat za P-glikoprotein.

Rimonabant displays high in vitro permeability and is not a substrate of P-glycoprotein.
Rimonabant ima in vitro veliko permeabilnost in ni substrat P- glikoproteina.

Pitolisant is not a substrate of OATP1B1, OATP1B3.
Pitolizant ni substrat OATP1B1 in OATP1B3.

In-vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.
Raziskave in vitro kažejo, da ertapenem ne zavira s P-glikoproteinom posredovanega transporta digoksina ali vinblastina in da ertapenem ni substrat za s P-glikoproteinom posredovani transport.

Ulipristal acetate is not a substrate for either OATP1B1 or OATP1B3.
Ulipristalacetat ni substrat za OATP1B1 ali OATP1B3.

A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4(e. g. beclomethasone).
Razmisliti je treba o zmanjšanju odmerka glukokortikoida ob sočasnem skrbnem nadziranju lokalnih in sistemskih učinkov ali o zamenjavi z glukokortikoidom, ki ni substrat za CYP3A4(npr. beklometazon).

In vitro, ataluren is not a substrate for the p-glycoprotein transporter.
In vitro ataluren ni substrat prenašalca p-glikoproteina.

A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4(eg, beclomethasone).
Razmisliti je treba o zmanjšanju odmerka glukokortikoida in skrbno nadzirati morebiten pojav lokalnih ali sistemskih učinkov ali glukokortikoid zamenjati s takšnim, ki ni substrat za CYP3A4(npr. beklometazon).

Enzalutamide is not a substrate of the efflux transporters P-gp or BCRP.
Enzalutamid ni substrat efluksnih prenašalcev P-gp ali BCRP.

A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4(e. g. beclomethasone).
Presoditi je treba o zmanjšanju odmerka glukokortikosteroida in skrbno spremljati lokalne in sistemske učinke ali obstoječi glukokortikosteroid zamenjati s takšnim, ki ni substrat za CYP 3A4(na primer beklometazonom).

Lenvatinib is not a substrate for OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, or the BSEP.
Lenvatinib ni substrat za OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2 ali BSEP.

In vitro studies indicated that eluxadoline is a substrate and an inhibitor of the hepatic uptake transporter OATP1B1; a substrate for the hepatic efflux transporter MRP2 and is not a substrate or inhibitor of the P-gp and BCRP transporters.
Študije in vitro so pokazale, da je eluksadolin substrat in zaviralec jetrnega privzemnega prenašalca OATP1B1, substrat jetrnega izločevalnega prenašalca MRP2 in ni substrat ali zaviralec prenašalcev P-gp in BCRP.

Telbivudine is not a substrate, inhibitor or inducer of the cytochrome P450(CYP450) enzyme system.
Telbivudin ni niti substrat niti zaviralec ali induktor encimskega sistema citokroma P450(CYP450).

It is unlikely that atosiban is involved in cytochrome P450 mediated drug-drug interactions as in vitro investigations have shown that atosiban is not a substrate for the cytochrome P450 system, and does not inhibit the drug metabolising cytochrome P450 enzymes.
Ni verjetno, da bi bil atosiban vpleten v medsebojno delovanje zdravil, posredovano s citokromom P450; preiskave in vitro namreč kažejo, da atosiban ni substrat sistema citokroma P450 in ne zavira encimov citokroma P450, ki presnavljajo zdravila.

Trametinib is not a substrate of CYP enzymes or of the transporters BCRP, OATP1B1, OATP1B3, OATP2B1, OCT1, MRP2, and MATE1.
Trametinib ni substrat encimov CYP ali prenašalcev BCRP, OATP1B1, OATP1B3, OATP2B1, OCT1, MRP2 in MATE1.

It is unlikely that atosiban is involved in cytochrome P450 mediated drug-drug interactions as in vitro investigations have shown that atosiban is not a substrate for the cytochrome P450 system, and does not inhibit the drug metabolising cytochrome P450 enzymes.
Verjetnost, da je atosiban vpleten v interakcije z drugimi zdravili, ki se presnavljajo z encimi citokrom P450 je majhna, saj in vitro raziskave kažejo, da atosiban ni substrat za encime citokrom P450 in ne zavira encimov citokrom P450, ki presnavljajo zdravila.

Telbivudine is not a substrate, inhibitor or inducer of the cytochrome P450(CYP450) enzyme system(see section 5.2).
Telbivudin ni niti substrat niti zaviralec ali induktor encimskega sistema citokroma P450(CYP450)(glejte poglavje 5.2).

In vitro, apremilast has little to no inhibitory effect(IC50gt; 10µM) on Organic Anion Transporter(OAT)1 and OAT3, Organic Cation Transporter(OCT)2, Organic Anion Transporting Polypeptide(OATP)1B1 and OATP1B3, or breast cancer resistance protein(BCRP) and is not a substrate for these transporters.
In vitro ima apremilast malo ali nič zaviralnega učinka(IC50gt; 10µM) na prenašalca organskih anionov (OAT)1 in OAT3, prenašalca organskih kationov (OCT)2, polipeptidnega prenašalca organskih anionov (OATP)1B1 in OATP1B3 ali na protein odpornosti proti raku dojke in ni substrat teh prenašalcev.

Based on in vitro studies lurasidone is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP4A11, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP2E1 enzymes.
Na podlagi študij in vitro lurasidon ni substrat za encime CYP1A1, CYP1A2, CYP2A6, CYP4A11, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 ali CYP2E1.

It is not a substrate for 5α-reductase, as it is already 5α-reduced, and hence is not potentiated in so-called“androgenic” tissues such as the skin, hair follicles, and prostate gland.
To ni substrat za 5α-reduktazo, saj je že 5α-zmanjšana in zato ni potencirana v tako imenovanih"androgenih" tkivih, kot so koža, folikli las in prostata.

In vitro data indicate that enzalutamide is not a substrate for OATP1B1, OATP1B3, or OCT1; and N-desmethyl enzalutamide is not a substrate for P-gp or BCRP.
Podatki in vitro kažejo, da enzalutamid ni substrat OATP1B1, OATP1B3 ali OCT1; in N-desmetil enzalutamid ni substrat za P-gp ali BCRP.

Degarelix is not a substrate for the human CYP450 system and has not been shown to induce or inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4/ 5 to any great extent in vitro.
Degareliks ni substrat humanega sistema CYP450 in zanj niso dokazali, da bi in vitro v večjem obsegu induciral ali inhibiral CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 ali CYP3A4/ 5.

In vitro studies indicate that raltegravir is not a substrate of cytochrome P450(CYP) enzymes, does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A, does not induce CYP3A4 and does not inhibit P-glycoprotein-mediated transport.
Študije in vitro kažejo, da raltegravir ni substrat za encime citokroma P450(CYP), ne zavira CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 ali CYP3A, ne inducira CYP3A4 in ne zavira s.

Raltegravir is not a substrate of cytochrome P450(CYP) enzymes, does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A, and does not induce CYP3A4.
Raltegravir ni substrat za encime citokroma P450(CYP), ne zavira CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 ali CYP3A in ne inducira CYP3A4.

Obinutuzumab is not a substrate, inhibitor, or inducer of cytochrome P450(CYP450), uridine diphosphate glucuronyltransferase(UGT) enzymes and transporters such as P-glycoprotein.
Obinutuzumab ni substrat, zaviralec ali induktor citokroma P450(CYP450), encimov uridindifosfat- glukuroniltransferaze(UGT) ali prenašalcev, kakršen je P-glikoprotein.

In vitro, brivaracetam is not a substrate of human P- glycoprotein(P-gp), multidrug resistance proteins(MRP) 1 and 2, and likely not organic anion transporter polypeptide 1B1(OATP1B1) and OATP1B3.
Brivaracetam in vitro ni substrat za človeški P-glikoprotein(P-gp), proteine odporne proti večim učinkovinam 1 in 2 in verjetno ne za organski anionski prenašalni polipeptid 1B1(OATP1B1) in OATP1B3.

In addition, migalastat is not a substrate for MATE1, MATE2-K, OAT1, OAT3, or OCT2, nor is it an inhibitor of OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2-K human uptake transporters.
Poleg tega migalastat ni substrat humanih privzemnih prenašalcev MATE1, MATE2-K, OAT1, OAT3 in OCT2 ali inhibitor humanih privzemnih prenašalcev OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1 in MATE2-K.

In vitro studies show that perampanel is not a substrate or significant inhibitor of organic anion transporting polypeptides(OATP) 1B1 and 1B3, organic anion transporters(OAT) 1, 2, 3, and 4, organic cation transporters(OCT) 1, 2, and 3, and the efflux transporters P-glycoprotein and Breast Cancer Resistance Protein(BCRP).
Študije in vitro kažejo, da perampanel ni substrat ali pomemben zaviralec organskih anionskih transportnih polipeptidov(OATP) 1B1 in 1B3, organskih anionskih transporterjev(OAT) 1, 2, 3 in 4, organskih kationskih transporterjev(OCT) 1, 2 in 3 in efluksnih transporterjev P-glikoproteina in proteina dovzetnosti za raka dojke(BCRP- Breast Cancer Resistance Protein).

In vitro studies indicated that loxapine was not a substrate for P-glycoprotein(P-gp), but does inhibit P-gp.
In vitro študije so pokazale, da loksapin ni substrat za P-glikoprotein(P-gp), vendar pa zavira P-gp.

In vitro, dolutegravir was not a substrate of human OATP 1B1, OATP 1B3 or OCT 1.
In vitro dolutegravir ni bil substrat za humani OATP 1B1, OATP 1B3 ali OCT 1.